Ediz DALKILIÇ, Mustafa Ferhat ÖKSÜZ, Nagehan DİK KUTLU, Ayşe Nur TUFAN, Belkıs Nihan COŞKUN, Selime ERMURAT, Yavuz PEHLİVAN, Güven ÖZKAYA

3423

Anti-TNF- Kesilmiş Romatoid Artrit, Ankilozan Spondilit ve Psöriatik Art rit Hastalarındaki Hastalık Sürecinin Değerlendirilmesi ? Tedavi ile Remisyon Sağlanmış ve Tedavisi

TNF-? inhibitör (TNFi) tedavisi ile remisyon elde edilmiş, tedaviye ara verilmiş inflamatuar romatolojik hastalık (İRH) tanılı bireylerin seyrini ortaya koymayı amaçladık. Hastalar geriye dönük olarak incelendi. C-reaktif protein (CRP), eritrosit sedimantasyon hızı (ESR) yanı sıra hastalık aktivite ölçütleri göz önünde bulunduruldu. Çalışmamıza 64 İRH (22 Romatoid Artrit (RA), 37 Ankilozan Spondilit (AS), 5 Psöriatik Artrit (PsA)) tanılı hasta dahil edildi. TNFi kesilmesiyle toplam 58 hastada reaktivasyon gelişmişti. Reaktivasyona kadar geçen süre ortalama 6 aydı. Hastaların 28' inde (%46) ilk 6 ay içinde reaktivasyon görülürken, 47' sinde (%73) ilk yılda reaktivasyon görülmüştü. TNFi kullanım süreleri ile reaktivasyon arasındaki ilişki incelendiğinde RA hastalarında TNFi kullanım süresi arttıkça reaktivasyona kadar geçen sürenin azalmış olduğu görüldü (p

The Assestment of The Course of Disease in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatıc Arthritis in whom the Remisson had been Maintained by Anti-TNF-? Medication and then Medication had been Ceased

We aimed to observe the course of individuals with diagnosis of inflammatory rheumatic diseases (IRD) whose remission had been maintained with TNF-? inhibitor (TNFi) therapy, and medication had been suspended. Patients were assessed retrospectively. Patients were assessed with C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity index. Sixty four patients with IRD (22 Rheumatoid Arthritis (RA), 37 Ankylosing Spondylitis (AS), 5 Psoriatic Arthritis (PsA)) were included in our study. Reactivation had been occurred in 58 patients after the cessation of TNFi. The average period until the reactivation was 6 months. Reactivation had been observed in the first year in 47 patients (73%) whereas it occurred in 28 patients (46%) in the first 6 months. Reactivation occurred in the majority of the patients with the cessation of TNFi medication. When the correlation between the TNFi medication periods and the reactivation has been evaluated, it was seen that the time until the reactivation was reduced when the duration of TNFi usage period had been prolonged (p
PDF

___

  • Firestein GS, Harris ED, Genovese MC. Rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Kel- ley'sTextbook of rheumatology. 7th ed. Philadelphia: WB Saunders, 2005: 996-1100.
  • Van der Linden S, Van der Heijde D, Braun J. Ankylosing spondylitis In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Textbook of rheumatology, 7th ed. Philadelphia: WB Saunders; 2005:1125-41.
  • Dafna DG. Psoriatic arthritis: In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Kelley's Textbook of rheumatology. 7th ed. Philadelphia: WB Saunders, 2005: 1155-64.
  • Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001 Feb 23;104(4):487-501.
  • Keat A, Barkham N, Bhalla A, et al: BSR guidelines for presc- ribing TNF-? blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumato- logy. Rheumatology (Oxford). 2005;44(7):939-47.
  • Tütüncü Z, Kavanaugh A: Anticytokine Therapies. Kelley's Textbook of Rheumatology, 9th Edition Firestein GS, Budd RC, Gabriel SE, et al. Expert Consult Premium Edition, Enhanced Online Features and Print, 2012; Chapter 63;957.
  • Brocq O, Millasseau E, Albert C, et al: Effect of discontinuing TNF alpha antagonist therapy in patients with remission of rhe- umatoid arthritis. Joint Bone Spine. 2009 Jul;76(4):350-5.
  • Tanaka Y, Hirata S, Kubo S, et al: Discontinuation of adali- mumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. AnnRheumDis. 2015 Feb;74(2):389-95.
  • Prince FH, Twilt M, Simon SC, et al: When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. AnnRheumDis 2009;68:1228-9.
  • Nawata M, Saito K, Nakayamada S, Tanaka Y: Discontinuation of infliximab in rheumatoid arthritis patients in clinical remis- sion. Modern rheumatology / the Japan Rheumatism Associa- tion. 2008;18(5):460-4.
  • Van den Broek M, Klarenbeek NB, Dirven L, et al: Discontinu- ation of infliximab and potential predictors of persistent low di- sease activity in patients with early rheumatoid arthritis and di- sease activity score-steered therapy: subanalysis of the BeSt study. Annals of the rheumatic diseases. 2011 Aug;70(8):1389- 94.
  • Brocq O, Roux CH, Albert C, et al: TNFalpha antagonist continuation rates in 442 patients with inflammatory joint dise- ase. Joint Bone Spine. 2007 Mar;74(2):148-54.
  • Remesal A, DE Inocencio J, Merino R, et al: Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol. 2010 Sep;37(9):1970-1.
  • Baszis K, Garbutt J, Toib D, et al: Clinical Outcomes After Withdrawal of Anti-Tumor Necrosis Factor Therapy in Patients With Juvenile Idiopathic Arthritis: A Twelve-Year Experience. ArthritisRheum. 2011 Oct; 63 (10): 3163-8.
  • Kadar G, Balazs E, Soos B, et al: Disease activity after the discontinuation of biological therapy in inflammatory rheuma- tic diseases. ClinRheumatol. 2014 Mar;33(3):329-33.
  • Baraliakos X, Kiltz U, Heldmann F, et al: Withdrawal of biolo- gic therapy in axial spondyloarthritis: the experience in estab- lished disease. ClinExpRheumatol. 2013 (4 Suppl 78): 43-6.
  • Baraliakos X, Listing J, Brandt J, et al: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with inf- liximab. ArthritisResTher. 2005;7(3):439-44.
  • Sieper J, van der Heijde D, Dougados M, et al: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). AnnRheumDis. 2013 Jun;72(6):815-22.
  • Rudwaleit M, Haibel H, Baraliakos X, et al: The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. ArthritisRheum. 2009 Mar;60(3):717-27.
  • Cantini F, Niccoli L, Cassara E, et al: Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Bio- logics. 2012;6:201-6.
Uludağ Üniversitesi Tıp Fakültesi Dergisi-Cover
  • ISSN: 1300-414X
  • Başlangıç: 1975
  • Yayıncı: Seyhan Miğal
Arşiv
Sayıdaki Diğer Makaleler

Anti-TNF- Kesilmiş Romatoid Artrit, Ankilozan Spondilit ve Psöriatik Art rit Hastalarındaki Hastalık Sürecinin Değerlendirilmesi ? Tedavi ile Remisyon Sağlanmış ve Tedavisi

Ediz DALKILIÇ, Mustafa Ferhat ÖKSÜZ, Nagehan DİK KUTLU, Ayşe Nur TUFAN, Belkıs Nihan COŞKUN, Selime ERMURAT, Yavuz PEHLİVAN, Güven ÖZKAYA